摘要
目的探讨雷贝拉唑与埃索美拉唑治疗反流性食管炎的成本-效果。方法将本院2011年6月—2013年12月收治的140例反流性食管炎患者随机分为雷贝拉唑组与埃索美拉唑组,每组各70例,比较两组患者的临床效果和成本-效果。结果雷贝拉唑组患者的总有效率为95.7%,埃索美拉唑组患者的总有效率为90.0%,差异无统计学意义(P>0.05)。雷贝拉唑组的C/E为33.5,ΔC/ΔE为60.0;埃索美拉唑组的C/E为27.9,ΔC/ΔE为10.6,埃索美拉唑组的成本-效果优势明显。结论埃索美拉唑治疗反流性食管炎的效果较佳,药物经济学优势更加,值得临床推广应用。
Objective To explore the cost-effectiveness analysis of rabeprazole and esomeprazole in treatment of reflux esophagitis. Methods 140 patients with reflux esophagitis were treated in our hospital from June 2011 to December 2013, they were randomly divided into rabeprazole group and esomeprazole group, each group of 70 cases, the clinical effect and cost-effectiveness in two groups were compared. Results The total effective rate was 95.7% in rabeprazole group, The total effective rate was 90.0% in es-omeprazole group, there was no statistically significant difference （P〉0.05）. The C/E was 33.5 in rabeprazole group, the ΔC/ΔE was 60.0. The C/E was 27.9 in esomeprazole group, the ΔC/ΔE was 10.6, the cost-effectiveness advantage was obvious in esomepra-zole group. Conclusion The effect of esomeprazole in treatment of reflux esophagitis is better, the pharmacoeconomics advantage more, it is worthy of clinical popularization and application.
出处
《中国卫生产业》
2014年第18期5-6,共2页
China Health Industry
